<DOC>
	<DOC>NCT02722135</DOC>
	<brief_summary>This is an open-label, dose-escalating trial to evaluate the MTD and/or dose to be used for further development by evaluation of DLT in course 1 and the safety of volasertib when added to standard intensive salvage chemotherapy with DNX-FLA in paediatric patients with AML after failure of first-line therapy. Furthermore, data on efficacy and PK/PD of volasertib in paediatric patients with AML when added to standard intensive salvage chemotherapy will be collected.</brief_summary>
	<brief_title>A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Inclusion criteria: Patients 3 months to &lt;18 years of age at the time of informed consent Patients with AML after failure of the frontline intensive AML therapy Lansky score at screening &gt;=50 for patients from 3 months to &lt;12 years Karnofsky score at screening &gt;=50 for patients from 12 to &lt;18 years Use of highly effective methods of birthcontrol, if sexually active Parents/legal guardians and patients have given written informed consent and informed assent suitable for the respective age group Exclusion criteria: Down syndrome Acute promyelocytic leukaemia and treatmentrelated AML QTc prolongation LVSF &lt;30% Cardiac disease and/or dysfunction Active uncontrolled infection HIV infection, acute or chronic hepatitis Inadequate lab parameters Impaired renal function Pregnancy or nursing Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>